Clinical outcomes and trials of patients with NSCLC bearing HER3, HER4 and NRG alterations
| Study | Phase | Patients (n) | Drugs | NSCLC patient cohort | ORR | mPFS (months) | Ref. |
|---|---|---|---|---|---|---|---|
| NCT03260491 | Phase I | 57 | Paritrutumab-deruxtecan | Locally advanced or metastatic EGFR mutant, pretreated (TKI) | 39% | 8.3 | 184 |
| NCT03260491 expansion cohort | Phase I | 47 | Paritrutumab-deruxtecan | Locally advanced or metastatic without EGFR mutation, pretreated (platinum-based chemotherapy ± immunotherapy) | 28% | 5.4 | 142 |
| NCT04676477 | Phase I | Enrolling | Paritrutumab-deruxtecan + osimertinib | Locally advanced or metastatic EGFR mutant, pretreated (osimertinib) | n.n. | n.n. | 185 |
| eNRGy1 | Global multicenter registry | 20 | Afatinib | NSCLC with NRG1 rearrangements | 25% | 2.8 | 154 |
| 15 | Chemotherapy | NSCLC with NRG1 rearrangements | 13%–14% | 4.0-5.8 | |||
| 9 | Chemoimmunmotherapy | NSCLC with NRG1 rearrangements | 0% | 3.3 | |||
| 5 | Immunotherapy | NSCLC with NRG1 rearrangements | 20% | 3.6 | |||
| eNRGy trial (NCT02912949) | Phase II | 46 | Zenocutuzumab (MCLA-128) | NRG1 fusion-positive NSCLC (pretreated) | 35% | n.n. | 186 |